Enveric Biosciences, Inc. (ENVB)

Stock Price: $4.30 USD 0.28 (6.97%)

Updated Jan 26, 2021 4:00 PM EST - Market closed

After-hours: $4.34 +0.04 (0.93%) Jan 26, 7:54 PM

Market Cap	54.67M
Revenue (ttm)	35.41M
Net Income (ttm)	-7.28M
Shares Out	1.32M
EPS (ttm)	-9.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Dividend Yield	n/a

Trading Day	January 26
Last Price	$4.30
Previous Close	$4.02
Change ($)	0.28
Change (%)	6.97%
Day's Open	4.10
Day's Range	4.03 - 4.41
Day's Volume	2,363,599
52-Week Range	2.62 - 14.80

News

Hide News

PRNewsWire - 5 days ago

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Enveric Biosciences, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

NEW YORK, Jan. 21, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiducia...

PRNewsWire - 1 week ago

Enveric Biosciences Inc. Announces Closing of $10 Million Registered Direct Offering

NAPLES, Fla., Jan. 15, 2021 /PRNewswire/ -- Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-first biotechnology company developing novel cannabinoid medicines ...

PRNewsWire - 3 weeks ago

Ameri Holdings Completes Spin-Off and Tender Offer, Changes Name to Enveric Biosciences and Begins Trading on the Nasdaq Under the Symbol "ENVB"

NAPLES, Fla., Dec. 31, 2020 /PRNewswire/ -- Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), formerly AMERI Holdings, Inc. (NASDAQ: AMRH), a patient-centric biotechnology...

Other stocks mentioned: AMRH

About ENVB

Jay Pharma develops evidence-based cannabinoid products and combination therapies cure effects of cancer treatment. The company was incorporated in 2017 and is based in Toronto, Canada.

Industry Biotechnology	Founded 1994
CEO Brent Kelton	Country United States
Stock Exchange NASDAQ	Ticker Symbol ENVB

Full Company Profile

Financial Performance

In 2019, ENVB's revenue was $39.91 million, a decrease of -7.17% compared to the previous year's $43.00 million. Losses were -$5.61 million, -66.81% less than in 2018.

Financial Statements